AstraZeneca Hedges Threat to Oncology Portfolio — Market Talk
AstraZeneca is hedging against a key threat to its antibody drug conjugate portfolio through its collaboration with Summit Therapeutics, Citi analysts say in a research note. The agreement has limited immediate impact, but it is a sensible move by the U.K. drugmaker in case medicines like Summit's…